Table 3.

Changes in Primary and Secondary Outcomes Between Baseline and 6 Months and Baseline and 12 Months

	Usual care ITT (N = 727)		SMA ITT* (N = 810)		SMA attendee† (N = 588)		SMA engagement‡ (N = 436)		Between-group 6-month differences (p value)			Between-group 12-month differences (p value)
	0- to 6-month change	0- to 12-month change	0- to 6-month change	0- to 12-month change	0- to 6-month change	0- to 12-month change	0- to 6-month change	0- to 12-month change	SMA ITT v usual care ITT	SMA attendee v usual care ITT	SMA engagement v Usual care ITT	SMA ITT v usual care ITT	SMA attendee v usual care ITT	SMA engagement v usual care ITT
Physiologic measures
A1c (%)	− 0.66 (< .001)§	− 0.79 (< .001)	− 1.01 (< .001)	− 0.95 (< .001)	− 1.08 (< .001)	− 1.00 (< .001)	− 1.19 (< .001)	− 1.08 (< .001)	− 0.35 (0.001)	− 0.42 (< 0.001)	− 0.53 (< 0.001)	− 0.16 (0.12)	− 0.21 (0.07)	− 0.29 (0.06)
SBP (mmHg)	0.88	− 0.80	− 0.47	0.63	− 0.80	− 0.42	− 0.41	− 0.85	− 1.35 (0.340)	− 1.88 (0.219)	− 2.05 (0.234)	1.43 (0.316)	0.17 (0.911)	− 0.82 (0.634)
† Med change measures‖
Insulin starts (yes/no)	0.72	0.69	2.17 (< .001)	2.09 (< .001)	2.44 (< .001)	2.86 (< .001)	2.69 (< .001)	3.59 (< .001)	3.00 (0.006)	3.56 (0.003)	4.60 (0.005)	3.02 (0.005)	3.80 (0.002)	5.68 (0.001)
Statin starts (yes/no)	0.81	0.69*	1.35	1.23	1.55	1.51	2.07 (< .001)	1.99 (< .001)	1.67 (0.067)	1.93 (0.034)	2.83 (0.006)	1.79 (0.037)	2.31 (0.007)	2.63 (0.011)
Anti-HTN med class changes	1.02	1.02	1.01	1.01	1.01	1.02	1.01	1.01	0.99 (0.823)	0.97 (0.690)	0.99 (0.839)	0.99 (0.849)	0.99 (0.897)	0.99 (0.854)

*Includes all those scheduled for an SMA

†Includes all those who attended ≥ 1 SMA

‡Includes all those who attended ≥ ½ of SMAs in series

§p value of intra-group change from baseline

‖Values for Insulin starts and Statin starts are odds ratios, and values for anti-hypertensive medication class changes are incidence rate ratios